The Labcorp sale transforms OPKO into a pure-play biopharma company, removing the loss-making diagnostics segment. Watch for regulatory approval timeline and closing conditions for the $722M deal, and whether the $125M royalty financing signals further capital needs or a bridge to closing.
Drug in focus
OPK drug pipeline →OPK-8801001
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1/2a
- Time to market
- At least 5-7 years, assuming successful completion of Phase 1/2a, Phase 2, and Phase 3 trials followed by regulatory filing and review.
- Next catalyst
- None dated
What to watchOPK-8801001 just began Phase 1/2a dosing on October 27, 2026, so the next meaningful catalyst is initial safety and pharmacodynamic data, likely not for 12+ months. For OPKO Health, the bigger near-term drivers are the Labcorp/BioReference asset sale closing and NGENLA royalty revenue trends. This early-stage program is unlikely to move the stock in the foreseeable future.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $1.75entry
- T+1 · 11d ago −1.14%α −1.46% · $1.73
- T+5 · 5d ago −4.57%α −7.86% · $1.67
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M consensus which included discontinued diagnostics revenue now reclassified. Net loss from continuing operations was $35.5M ($0.05 per share), versus consensus EPS of -$0.06. The headline event is the agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M in cash at closing plus up to $150M in contingent consideration, and a $125M senior secured royalty financing with HealthCare Royalty.
Key Financial Metrics
Key Facts
- Agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M cash at closing plus up to $150M contingent on 4Kscore sales
- Issued $125M additional senior secured royalty notes to HealthCare Royalty, secured by mazdutide royalty payments from Eli Lilly
- Continuing operations revenue $65.4M (+16% YoY), above consensus of $136.6M which included discontinued diagnostics
- Net loss from continuing operations $35.5M ($0.05 per share) vs consensus EPS -$0.06
- Withdrew previously issued guidance for services revenue and total costs and expenses due to pending Labcorp transaction
- Cash, cash equivalents and restricted cash $403.2M as of September 30, 2026
- Repurchased 7,050,000 shares for $10.6M during Q3; $84.3M remaining under $200M buyback authorization
Financial Impact
Sale of BioReference for $722M cash plus up to $150M contingent; $125M additional royalty financing; continuing operations revenue $65.4M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Global Products | $48.4M | +22.8% |
| Innovative Biotech | $17.0M | 0.0% |
Risk Factors
- Labcorp transaction subject to regulatory approvals and customary closing conditions; may not close or may be delayed
- Withdrawn guidance creates near-term uncertainty for revenue and cost forecasts
- Discontinued operations generated a $18.0M loss in Q3 2026, and are guided to lose $35M-$45M in Q4 2026
- Senior secured royalty financing increased to $370.2M, adding leverage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-447357 |
| Document: opk-20261104.htm | 0001193125-26-447357 |
| Document: 0001193125-26-447357-index-headers.html | 0001193125-26-447357 |
| Document: 0001193125-26-447357-index.html | 0001193125-26-447357 |
| Document: 0001193125-26-447357.txt | 0001193125-26-447357 |
| 8-K Data (Synthetic) | 0001193125-26-447357 |
Track record
10 reports on OPK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 4, 202612d ago 8-K Neutral 6/10 Viewing Entry $1.75 Now $1.62 −7.43% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 6/10 No price data
- Oct 15, 20264w ago 8-K Bullish 7/10 Entry $1.53 to $1.68 Now $1.62 +5.88% ▲ +9.80% +10.97% vs SPY
- Jul 27, 202616w ago 8-K Mixed 5/10 Entry $1.65 to $1.49 Now $1.62 −1.82% ▼ −9.70% −13.08% vs SPY
- Jul 23, 202616w ago Press Release Neutral 1/10 Entry $1.17 to $1.46 Now $1.62 +38.46% ▲ +24.79% +21.48% vs SPY
- Jun 15, 202622w ago Press Release Neutral 3/10 Entry $1.40 to $1.23 Now $1.62 +15.71% ▼ −12.14% −11.39% vs SPY
- May 15, 202626w ago DEFA14A Neutral 4/10 Entry $1.13 to $1.39 Now $1.62 +43.36% ▲ +23.01% +21.43% vs SPY
- Apr 30, 202628w ago Press Release Neutral 4/10 Entry $1.13 to $1.43 Now $1.62 +43.36% ▲ +26.55% +21.58% vs SPY
- Apr 22, 202629w ago Press Release Bullish 7/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
- Apr 21, 202629w ago Press Release Neutral 1/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers